Table 3. Treatment Effect on Symptom and Function Outcomesa.
| Measurement | Mean (95% CI) | P Value | ||||
|---|---|---|---|---|---|---|
| Triamcinolone (n = 70) |
Saline (n = 70) |
Between-Group Difference in Change | ||||
| Baseline | 2-Year Change | Baseline | 2-Year Change | |||
| WOMACb | ||||||
| Pain | 7.50 (6.3 to 8.6) | −1.2 (−1.9 to −0.58) | 8.2 (7.0 to 9.3) | −1.9 (−2.52 to −1.23) | −0.64 (−1.6 to 0.29) | .17 |
| Function | 27.1 (23.1 to 31.0) | −4.1 (−7.4 to −0.83) | 29.2 (25.3 to 33.1) | −5.1 (−8.1 to −2.19) | −1.01 (−4.9 to 2.9) | .59 |
| Stiffness | 3.5 (3.0 to 4.1) | −0.59 (−1.1 to −0.06) | 3.8 (3.3 to 4.3) | −0.53 (−1.0 to −0.01) | −0.06 (−0.43 to 0.56) | .79 |
| VAS Pain scorec | 30.8 (22.9 to 38.7) | −2.7 (−11.9 to 6.6) | 35.4 (27.6 to 43.2) | −7.6 (−15.4 to 0.16) | −5.0 (−13.9 to 3.9) | .26 |
| Function tests, sd | ||||||
| 20-m Walk | 20.6 (19.0 to 22.2) | −0.29 (−1.03 to 0.44) | 19.2 (17.7 to 20.8) | 0.14 (−0.58 to 0.86) | 0.43 (−0.62 to 1.5) | .41 |
| Chair stand | 22.1 (19.0 to 25.2) | −1.1 (−3.5 to 1.2) | 21.2 (18.1 to 24.2) | −1.2 (−3.6 to 1.1) | −0.11 (−2.8 to 2.6) | .94 |
| Acetaminophen usee | .43 | |||||
| None | 5 | −2 | 9 | −6 | −4 | |
| % (95% CI) | 7.1 (1.1 to 13.1) | −2.8 (−10.5 to 4.9) | 12.9 (5.0 to 20.8) | −8.6 (−17.8 to 0.6) | −5.8 (−17.8 to 6.2) | |
Abbreviations: KL, Kellgren-Lawrence; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities.
a
Estimates and test for treatment by time interaction from repeated-measures, random intercept model, adjusted for KL, sex, and acetaminophen use. Time used is months from baseline exam as a linear trend.
b
See the Methods section for WOMAC scores for pain, stiffness, and function.
c
Values range from 0 to 100, for which 0 indicates no pain; 100, extreme pain.
d
Higher values for walk time and chair-stand indicate worse function.
e
Test for treatment by time interaction in a repeated-measures generalized estimating equation model, unadjusted for KL and sex.